 Achieved record quarterly revenues of 21.5 million for Q22021, 4.5 increase from Q12021 despite challenging market conditions; Cash balance1 of approximately 71.5 million as of June 30, 2021 Record Talicia quarterly prescription volume up more than 10; Movantik quarterly new prescriptions up 5.6; Talicia and Movantik coverage expanded to 8 and 9 out of 10 commercially insured Americans, respectively Opaganib in final stages of selection by Quantum Leap Healthcare Collaborative and BARDA for inclusion in the I-SPY COVID-19 platform trial with funding provided by BARDA New preclinical data supports opaganibs potent inhibition of Delta COVID-19 variant Top-line results from global Phase 23 COVID-19 study upcoming following completion of treatment and follow-up Primary endpoint met in the ongoing prostate cancer Phase 2 study of opaganib, based on a preliminary review of partial unaudited data; patient accrual, treatment and analysis ongoing Management to host webcast today, at 8:30 a.m. EST TEL AVIV, ISRAEL and RALEIGH, NC ACCESSWIRE August 26, 2021 RedHill Biopharma Ltd. 